Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation

European Journal of Cancer

Volumn 49, Issue 4, 2013, Pages 826-834

  Kim, Beom Kyung ^a,b   Kim, Kyung Ah ^a   Park, Jun Yong ^a,b   Ahn, Sang Hoon ^a,b,c   Chon, Chae Yoon ^a,b   Han, Kwang Hyub ^a,b,c   Kim, Seung Up ^a,b   Kim, Myeong Jin ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Liver Cirrhosis Clinical Research Centre   (South Korea)

^c Brain Korea 21 Project for Medical Science   (South Korea)

Author keywords

EASL; Equivalence; mRECIST; Overall survival; Prediction

Indexed keywords

ALPHA FETOPROTEIN; DOXORUBICIN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT RESPONSE;

ADULT; AGED; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84873713980     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.08.022     Document Type: Article

References (28)

1. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting results of cancer treatment Cancer 47 1981 207 214
2. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
3. J. Bruix, M. Sherman, and J.M. Llovet Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver J Hepatol 35 2001 421 430
4. R. Gillmore, S. Stuart, and A. Kirkwood EASL and mRECIST responses are independent prognostic factors for survival in hepatocellular cancer patients treated with transarterial embolization J Hepatol 55 2011 1309 1316
5. A. Riaz, K. Memon, and F.H. Miller Role of the EASL, RECIST, and WHO response guidelines alone or in combination for hepatocellular carcinoma: radiologic-pathologic correlation J Hepatol 54 2011 695 704
6. A. Riaz, F.H. Miller, and L.M. Kulik Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma JAMA 303 2010 1062 1069
7. K. Memon, L. Kulik, and R.J. Lewandowski Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times Gastroenterology 141 2011 526 535 535 e1-2
8. J.M. Llovet, A.M. Di Bisceglie, and J. Bruix Design and endpoints of clinical trials in hepatocellular carcinoma J Natl Cancer Inst 100 2008 698 711
9. R. Lencioni, and J.M. Llovet Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 2010 52 60
10. J. Edeline, E. Boucher, and Y. Rolland Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Cancer 118 2012 147 156
11. J.H. Shim, H.C. Lee, and S.O. Kim Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models Radiology 262 2012 708 718
12. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
13. Korean Liver Cancer Study Group and National Cancer Center Practice guidelines for management of hepatocellular carcinoma 2009 Korean J Hepatol 15 2009 391 423
14. D. Warr, S. McKinney, and I. Tannock Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response J Clin Oncol 2 1984 1040 1046
15. Zhou X, Obuchowski N, McClish D. Statistical methods in diagnostic medicine. John Wiley & Sons Inc.; 2002.
16. D. Altman Practical statistics for medical research 1991 Chapman & Hall London, England
17. A. Forner, C. Ayuso, and M. Varela Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable? Cancer 115 2009 616 623
18. K. James, E. Eisenhauer, and M. Christian Measuring response in solid tumors: unidimensional versus bidimensional measurement J Natl Cancer Inst 91 1999 523 528
19. K.H. Han, M. Kudo, and S.L. Ye Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia Oncology 81 Suppl. 1 2011 158 164
20. K.H. Han, and J.K. Kim Liver cancer in Korea Hepatol Res 37 Suppl. 2 2007 S106 S109
21. S.J. Shim, J. Seong, and K.H. Han Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma Liver Int 25 2005 1189 1196
22. T. Kawaguchi, K. Ohkawa, and K. Imanaka Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients Hepatogastroenterology 59 2012 219 223
23. J. Bruix, and M. Sherman Management of hepatocellular carcinoma: an update Hepatology 53 2011 1020 1022
24. S.S. Ahn, M.J. Kim, and J.S. Lim Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma Radiology 255 2010 459 466
25. C.K. Baek, J.Y. Choi, and K.A. Kim Hepatocellular carcinoma in patients with chronic liver disease: a comparison of gadoxetic acid-enhanced MRI and multiphasic MDCT Clin Radiol 67 2012 148 156
26. A. Riaz, L. Kulik, and R.J. Lewandowski Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres Hepatology 49 2009 1185 1193
27. A. Riaz, R.J. Lewandowski, and L. Kulik Radiologic-pathologic correlation of hepatocellular carcinoma treated with chemoembolization Cardiovasc Intervent Radiol 33 2010 1143 1152
28. Y.K. Maddala, L. Stadheim, and J.C. Andrews Drop-out rates of patients with hepatocellular cancer listed for liver transplantation: outcome with chemoembolization Liver Transpl 10 2004 449 455